Reaction
Prostatic Specific Antigen Abnormal reporting signals
As of the last recalculation, Prostatic Specific Antigen Abnormal appears in 1,032 FAERS reports alongside 16 co-occurring drug terms. The strongest observed disproportionality signal is LEUPROLIDE ACETATE (PRR 204.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Leuprolide Acetate | 447 | 204.3 | 205.5 |
| Bicalutamide | 70 | 99.3 | 99.8 |
| Enzalutamide | 199 | 84.4 | 84.6 |
| Abiraterone Acetate | 103 | 56.0 | 56.1 |
| Apalutamide | 31 | 54.8 | 54.9 |
| Abiraterone | 32 | 48.9 | 49.0 |
| Relugolix | 52 | 46.8 | 46.9 |
| Lutetium Lu 177 Vipivotide Tetraxetan | 24 | 37.6 | 37.7 |
| Febuxostat Tablets 40 Mg | 13 | 26.1 | 26.1 |
| Febuxostat Tablets 80 Mg | 13 | 26.1 | 26.1 |
| Goserelin | 15 | 22.9 | 22.9 |
| Olaparib | 21 | 20.6 | 20.7 |
| Febuxostat | 13 | 15.8 | 15.8 |
| Pazopanib Hydrochloride | 13 | 9.8 | 9.8 |
| Docetaxel Anhydrous | 28 | 8.6 | 8.6 |
| Docetaxel | 28 | 8.6 | 8.6 |